Universal- Beteiligungs- und Servicegesellschaft mbH
Position in ROIV — Roivant Sciences Ltd.
CIK 2057170
FRANKFURT AM MAIN, 2M
Position in ROIV
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$3,346,443
+$1,357,639 QoQ
Shares Held
94,559
+31.7% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#169
of 494 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Universal- Beteiligungs- und Servicegesellschaft mbH holds $732,771,778 across 106 Biotechnology names. ROIV ranks #40 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
323,752 | $160,817,330 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
100,286 | $62,532,332 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
157,223 | $47,328,839 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
134,388 | $32,383,476 | |
| 5 | INCY |
Incyte Corp
|
236,172 | $26,772,457 | |
| 6 | EXEL |
Exelixis, Inc.
|
452,133 | $24,600,556 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
233,499 | $18,514,135 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
48,118 | $16,109,425 |
All Filings in ROIV
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,346,443 | 94,559 | Shares | Defined | 2026-08-06 | |
| 2026-03-31 | $1,988,804 | 71,798 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $1,748,173 | 80,561 | Shares | Defined | 2026-01-28 | |
| 2025-09-30 | $638,591 | 42,207 | Shares | Defined | 2025-10-30 | |
| 2025-06-30 | $292,794 | 25,980 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $165,476 | 16,400 | Shares | Defined | 2025-05-06 | |
| 2024-12-31 | $194,012 | 16,400 | Shares | Defined | 2025-02-28 | |
| No filing history on record for this holder in this stock. | ||||||